Research And Development Tenders

Conclusion of Non-Exclusive Discount Agreements According to § 130 a Paragraph 8 Sgb V for Drugs with the Active Ingredient Epoetin Zeta

Oh-Biologika-2023-09 Lutropin Alfa/ Follitropin Alfa (Drug Combination)

Open House Original Discount Contracts 2023-12 - Tiotropium Bromide/Olodaterol (Combination of Active Substances)

Drugs with the Active Ingredient Ibuprofen (Atc: M01ae01 - Prescription Only, in Immediate-Release Dosage Form with the Strengths 400Mg and 600Mg)

Drugs with the Active Ingredient Ibuprofen (Atc: M01ae01 - in Sustained-Release Dosage Form with a Potency of 800 Mg)

Open House Procedure for Bicycle Leasing

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Formoterol Glycopyrronium Budesonide, Atc R03al11 for the Period June 1St, 2023 - May 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Tianeptine, Atc N06ax14 for the Period June 1St, 2023 - May 31St, 2025

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Zolmitriptan (N02cc03) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements According to §§ 130A Abs. 8/130C Abs. 1 Sgb V for Drugs with the Active Substance Natalizumab (L04aa23), S.C. Dosage Form as Part of an Open House Model.